FBRX

Forte Biosciences Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$455.65M
P/E Ratio
EPS
$-4.97
Beta
2.84
52W High
$35.80
52W Low
$9.10
50-Day MA
$21.42
200-Day MA
$22.82
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Forte Biosciences Inc

Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-76.90M
Operating Margin0.00%
Return on Equity-188.40%
Return on Assets-83.90%
Revenue/Share (TTM)$0.00
Book Value$2.36
Price-to-Book10.18
Price-to-Sales (TTM)
EV/Revenue-
EV/EBITDA1.87
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$20.48M
Float$18.83M
% Insiders2.13%
% Institutions74.84%

Historical Volatility

HV 10-Day
87.49%
HV 20-Day
71.02%
HV 30-Day
73.29%
HV 60-Day
81.01%
HV Rank
23.4%

Volatility is currently expanding

Analyst Ratings

Consensus ($63.75 target)
5
Buy

Latest News

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value = 0.020) Response to FB102 was observed early, with statistically significant improvements observed by the day 64 visit (p=0.023).

Business Wire7/9/2026Neutral
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c.

Business Wire5/11/2026Neutral
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102's potential to address the high unmet need in celiac disease. The clinical development for FB102 continue.

Business Wire5/11/2026Neutral
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive markets, represent major catalysts for FBRX in 2024.

Seeking Alpha4/10/2026Positive
Forte Biosciences Announces Pricing of $150 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and comm.

Business Wire4/9/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026